Petros Pharmaceuticals Reports Reduced Net Loss and Strategic Shift Amid Liquidity Concerns

Petros Pharmaceuticals, Inc. reported a net loss of $987,036 for the three months ended March 31, 2026, a significant reduction from the $2,260,022 loss recorded in the same period of the previous year. The company’s operating expenses decreased by 30% to $1,027,179, down from $1,458,349, primarily due to reduced professional service fees and other operating expenses. The decrease in losses was attributed to a lack of warrant issuance costs, which had previously amounted to $10,420,982 in the first quarter of 2025, and a gain from the change in fair value of warrant liability, which was absent in the latest quarter.

In terms of financial position, Petros reported total assets of $4.4 million as of March 31, 2026, down from $5.2 million at the end of 2025. Current liabilities increased to $2.6 million from $2.3 million, driven by higher accounts payable and accrued expenses. The company’s stockholders’ equity also declined significantly to $1.8 million from $2.9 million, reflecting an accumulated deficit of $112.3 million. The company’s cash and cash equivalents decreased to $4.4 million from $5.1 million, indicating a cash burn rate that raises concerns about liquidity.

Strategically, Petros has shifted its focus away from its previous product lines, including the discontinuation of Stendra® sales and the assignment of its subsidiaries to a third-party fiduciary for liquidation. The company is now concentrating on developing a proprietary integrated technology solutions platform aimed at facilitating the transition of prescription medications to over-the-counter status. This platform is still in early development stages and is expected to include both software as a service (SaaS) and software as a medical device (SaMD) components.

The company is currently exploring various financing strategies to address its liquidity challenges, as it does not have sufficient cash to fund operations for the next 12 months. Potential sources of financing include secured or unsecured debt, convertible debt, and equity offerings. However, there is no assurance that Petros will be able to raise the necessary capital. The company’s stock is now traded on the OTCID market following its delisting from Nasdaq, which may further limit its ability to attract investment and raise funds.

Looking ahead, Petros acknowledges the substantial doubt about its ability to continue as a going concern. The management is actively seeking to enhance its financial position through potential asset acquisitions and collaborations, but the success of these initiatives remains uncertain. The company’s future performance will largely depend on its ability to secure additional funding and successfully develop its new platform in the competitive pharmaceutical landscape.